[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Books, Journals, New Media
March 10, 1999

Trial DesignPharsight Trial Designer

Author Affiliations
 

Harriet S.MeyerMD, Contributing EditorJonathan D.EldredgeMLS, PhD, Journal Review EditorRobertHoganMD, adviser for new media

 

Not Available

JAMA. 1999;281(10):955-957. doi:10.1001/jama.281.10.955-JBK0310-5-1

Introduction: drug development is bigger and bigger business. The average cost of a compound is now $300 million, and the clinical trials to get the drug approved average about $100 million in cost. Most academicians see only a part of the process, and practicing clinicians see only the tail spout.

Outside medicine, industrial organizations increasingly turn to simulation to select courses of action. Aerospace and financial companies are especially known to do this. The Pharsight Corporation is gambling that this approach applies to pharmaceutical development as well as it does to the design and marketing of new airplanes. Their gamble may pay off: in the past year, they have absorbed other companies doing similar activity and are poised to be the leaders in the field of computer-assisted trial design (CATD).

First Page Preview View Large
First page PDF preview
First page PDF preview
×